Erratum: HER2 Ile655Val polymorphism contributes to breast cancer risk: Evidence from 27 case-control studies (Breast Cancer Research and Treatment DOI:10.1007/s10549-010-0886-z);HER2 Ile655Val polymorphism contributes to breast cancer risk: Evidence from 27 case-control studies

Breast Cancer Research and Treatment

Volumn 124, Issue 3, 2010, Pages 771-778

  Lu, Su ^a,b   Wang, Zhanwei ^c   Liu, Hong ^a,b   Hao, Xishan ^a,b  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; HER2; Meta analysis; Polymorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ISOLEUCINE; VALINE;

ARTICLE; ASIAN; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; EPIDEMIOLOGICAL DATA; ETHNIC DIFFERENCE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; NEGRO; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 78649324359     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1196-1     Document Type: Erratum

References (46)

1. NE Hynes DF Stern 1994 The biology of erbB-2/neu/HER-2 and its role in cancer Biochim Biophys Acta 1198 165 184 7819273
2. MA Olayioye RM Neve HA Lane NE Hynes 2000 The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J 19 3159 3167 1:CAS:528:DC%2BD3cXlt1ajtLY%3D 10.1093/emboj/19.13.3159 10880430
3. K Porter-Jordan ME Lippman 1994 Overview of the biologic markers of breast cancer Hematol Oncol Clin North Am 8 73 100 1:STN:280: DyaK2c3gtFWksA%3D%3D 8150784
4. S De Placido C Carlomagno M De Laurentiis AR Bianco 1998 c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients Breast Cancer Res Treat 52 55 64 10.1023/A:1006159001039 10066072 (Pubitemid 29056085)
5. F Revillion J Bonneterre JP Peyrat 1998 ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34 791 808 1:STN:280:DyaK1M%2FhsVChsA%3D%3D 10.1016/S0959-8049(97)10157-5 9797688 (Pubitemid 28248487)
6. N Prenzel OM Fischer S Streit S Hart A Ullrich 2001 The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification Endocr Relat Cancer 8 11 31 1:CAS:528:DC%2BD3MXkvFegurg%3D 10.1677/erc.0.0080011 11350724 (Pubitemid 32520251)
7. PM Siegel DL Dankort WR Hardy WJ Muller 1994 Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors Mol Cell Biol 14 7068 7077 1:CAS:528:DyaK2MXhsVWlsrc%3D 7935422
8. J Papewalis A Nikitin MF Rajewsky 1991 G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene Nucleic Acids Res 19 5452 1:CAS:528:DyaK3MXmslaht7s%3D 10.1093/nar/19.19.5452-a 1681519
9. D Xie XO Shu Z Deng WQ Wen KE Creek Q Dai YT Gao F Jin W Zheng 2000 Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk J Natl Cancer Inst 92 412 417 1:CAS:528:DC%2BD3cXhvFGhu70%3D 10.1093/jnci/92.5.412 10699071 (Pubitemid 30154823)
10. SW Baxter IG Campbell 2001 Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk J Natl Cancer Inst 93 557 559 1:STN:280:DC%2BD3M3gtVGjtw%3D%3D 10.1093/jnci/93.7.557 11287454
11. S Wang-Gohrke J Chang-Claude 2001 Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk J Natl Cancer Inst 93 1657 1659 1:STN:280:DC%2BD3Mnks1Squw%3D%3D 10.1093/jnci/93.21.1657 11698574
12. A Hishida N Hamajima H Iwata K Matsuo K Hirose N Emi K Tajima 2002 Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk J Natl Cancer Inst 94 1807 1808 1:CAS:528:DC%2BD38XptlOitLY%3D 12464653
13. C Keshava EC McCanlies N Keshava MS Wolff A Weston 2001 Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States Cancer Lett 173 37 41 1:CAS:528:DC%2BD3MXntV2jsb0%3D 10.1016/S0304-3835(01) 00671-1 11578807 (Pubitemid 32907507)
14. KG Montgomery DM Gertig SW Baxter RL Milne GS Dite MR McCredie GG Giles MC Southey JL Hopper IG Campbell 2003 The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years Cancer Epidemiol Biomarkers Prev 12 1109 1111 1:CAS:528:DC%2BD3sXosVCqsrc%3D 14578152
15. R Millikan A Eaton K Worley L Biscocho E Hodgson WY Huang J Geradts M Iacocca D Cowan K Conway L Dressler 2003 HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites Breast Cancer Res Treat 79 355 364 1:CAS:528:DC%2BD3sXktlagsr8%3D 10.1023/A:1024068525763 12846420 (Pubitemid 36750943)
16. E Kamali-Sarvestani AR Talei A Merat 2004 Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women Cancer Lett 215 83 87 1:CAS:528:DC%2BD2cXnslGhs7w%3D 15374636
17. E Akisik N Dalay 2004 Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk Exp Mol Pathol 76 260 263 1:CAS:528:DC%2BD2cXjs1CisrY%3D 10.1016/j.yexmp.2003.12.005 15126109 (Pubitemid 38569788)
18. D Pinto A Vasconcelos S Costa D Pereira H Rodrigues C Lopes R Medeiros 2004 HER2 polymorphism and breast cancer risk in Portugal Eur J Cancer Prev 13 177 181 1:STN:280:DC%2BD2c3mslymtA%3D%3D 10.1097/01.cej.0000130015.91525.c7 15167216 (Pubitemid 38780673)
19. TG Kalemi AF Lambropoulos M Gueorguiev S Chrisafi KT Papazisis A Kotsis 2005 The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece Cancer Lett 222 57 65 1:CAS:528:DC%2BD2MXjtlans7s%3D 10.1016/j.canlet.2004.11.025 15837541 (Pubitemid 40544847)
20. HJ An NK Kim D Oh SH Kim MJ Park MY Jung H Kang SG Kim KP Lee KS Lee 2005 Her2 genotype and breast cancer progression in Korean women Pathol Int 55 48 52 1:CAS:528:DC%2BD2MXivVymur0%3D 10.1111/j.1440-1827.2005.01789.x 15693849 (Pubitemid 40343723)
21. SE Nelson MN Gould JM Hampton A Trentham-Dietz 2005 A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer Breast Cancer Res 7 R357 R364 1:CAS:528:DC%2BD2MXivFygtLk%3D 10.1186/bcr1004 15987431
22. DG Cox SE Hankinson DJ Hunter 2005 The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk Pharmacogenet Genomics 15 447 450 1:CAS:528:DC%2BD2MXltlGjurc%3D 10.1097/01.fpc.0000166822.66754.c6 15970791
23. B Frank K Hemminki M Wirtenberger JL Bermejo P Bugert R Klaes RK Schmutzler B Wappenschmidt CR Bartram B Burwinkel 2005 The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk Carcinogenesis 26 643 647 1:CAS:528:DC%2BD2MXhslSrsrc%3D 10.1093/carcin/bgh342 15550452 (Pubitemid 41214155)
24. P Zubor A Vojvodova J Danko K Kajo N Szunyogh Z Lasabova K Biringer J Visnovsky K Dokus P Galajda L Plank 2006 HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia Neoplasma 53 49 55 1:STN:280:DC%2BD28%2FislKmtw%3D%3D 16416013
25. PR Benusiglio F Lesueur C Luccarini DM Conroy M Shah DF Easton NE Day AM Dunning PD Pharoah BA Ponder 2005 Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study Breast Cancer Res 7 R204 R209 1:CAS:528:DC%2BD2MXhslGis7o%3D 10.1186/bcr982 15743501
26. E Papadopoulou K Simopoulos G Tripsianis I Tentes K Anagnostopoulos E Sivridis G Galazios A Kortsaris 2007 Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer Neoplasma 54 365 373 1:CAS:528:DC%2BD1cXivVyhtw%3D%3D 17918664
27. S Tommasi V Fedele A Crapolicchio A Bellizzi A Paradiso SJ Reshkin 2003 ErbB2 and the antimetastatic nm23/NDP kinase in regulating serum induced breast cancer invasion Int J Mol Med 12 131 134 1:CAS:528:DC%2BD3sXltFGju7Y%3D 12792823
28. T Rajkumar M Samson R Rama V Sridevi U Mahji R Swaminathan NK Nancy 2008 TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy Breast Cancer Res Treat 112 81 87 1:CAS:528:DC%2BD1cXhtFOjtrnJ 10.1007/s10549-007-9821-3 18058229
29. A Siddig AO Mohamed H Kamal S Awad AH Hassan E Zilahi M Al-Haj R Bernsen A Adem 2008 HER-2/neu Ile655Val polymorphism and the risk of breast cancer Ann N Y Acad Sci 1138 84 94 10.1196/annals.1414.014 18837888
30. H Mutluhan E Akbas NE Erdogan F Soylemez MS Senli A Polat I Helvaci E Seyrek 2008 The influence of HER2 genotypes as molecular markers on breast cancer outcome DNA Cell Biol 27 575 579 1:CAS:528:DC%2BD1cXhtFKhurjO 10.1089/dna.2007.0702 18721072
31. SC Lee MF Hou PC Hsieh SH Wu LA Hou H Ma SM Tsai LY Tsai 2008 A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan Clin Biochem 41 121 125 1:CAS:528:DC%2BD1cXhsVOrsbk%3D 10.1016/j.clinbiochem.2007.11.005 18062925
32. R Naidu CH Yip NA Taib 2008 Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases Neoplasma 55 87 95 1:CAS:528:DC%2BD1cXjtVOgtrs%3D 18237245
33. Kallel I, Kharrat N, Al-fadhly S, Rebai M, Khabir A, Boudawara TS, Rebai A HER2 polymorphisms and breast cancer in Tunisian women. Genet Test Mol Biomarkers 14:29-35
34. J Little L Bradley MS Bray M Clyne J Dorman DL Ellsworth J Hanson M Khoury J Lau TR O'Brien N Rothman D Stroup E Taioli D Thomas H Vainio S Wacholder C Weinberg 2002 Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations Am J Epidemiol 156 300 310 12181099
35. Z Wang Y Fu C Tang S Lu WM Chu 2009 SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls Breast Cancer Res Treat 10.1007/s10549-009-0648-y
36. Z Wang D Cui W Lu 2010 SULT1A1 R213H polymorphism and breast cancer risk: a meta-analysis based on 8,454 cases and 11,800 controls Breast Cancer Res Treat 10.1007/s10549-010-0772-8
37. J Lau JP Ioannidis CH Schmid 1997 Quantitative synthesis in systematic reviews Ann Intern Med 127 820 826 1:STN:280:DyaK1c%2FgtVOmuw%3D%3D 9382404
38. R DerSimonian N Laird 1986 Meta-analysis in clinical trials Control Clin Trials 7 177 188 1:STN:280:DyaL2s7gsVamtA%3D%3D 10.1016/0197-2456(86)90046-2 3802833 (Pubitemid 17189972)
39. N Mantel W Haenszel 1959 Statistical aspects of the analysis of data from retrospective studies of disease J Natl Cancer Inst 22 719 748 1:STN:280:DyaG1M%2FosVOhtQ%3D%3D 13655060
40. M Egger G Davey Smith M Schneider C Minder 1997 Bias in meta-analysis detected by a simple, graphical test BMJ 315 629 634 1:STN:280: DyaK2svls1KjtA%3D%3D 9310563
41. P Casalini MV Iorio E Galmozzi S Menard 2004 Role of HER receptors family in development and differentiation J Cell Physiol 200 343 350 1:CAS:528:DC%2BD2cXmtlKju70%3D 10.1002/jcp.20007 15254961 (Pubitemid 39006925)
42. DF Stern 2003 ErbBs in mammary development Exp Cell Res 284 89 98 1:CAS:528:DC%2BD3sXitVylt7w%3D 10.1016/S0014-4827(02)00103-9 12648468 (Pubitemid 36331968)
43. KL Troyer DC Lee 2001 Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network J Mammary Gland Biol Neoplasia 6 7 21 1:STN:280:DC%2BD38%2FitlOksQ%3D%3D 10.1023/A:1009560330359 11467454 (Pubitemid 33640643)
44. CI Bargmann MC Hung RA Weinberg 1986 Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 Cell 45 649 657 1:CAS:528:DyaL28XksFGmtL8%3D 10.1016/0092-8674(86)90779-8 2871941
45. CT Guy MA Webster M Schaller TJ Parsons RD Cardiff WJ Muller 1992 Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease Proc Natl Acad Sci USA 89 10578 10582 1:CAS:528:DyaK3sXjs1ymsw%3D%3D 10.1073/pnas.89.22.10578 1359541
46. SJ Fleishman J Schlessinger N Ben-Tal 2002 A putative molecular-activation switch in the transmembrane domain of erbB2 Proc Natl Acad Sci USA 99 15937 15940 1:CAS:528:DC%2BD38Xps1egurk%3D 10.1073/pnas.252640799 12461170 (Pubitemid 35462727)